Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double attack on liver tumors: radiotherapy plus chemoembolization

NCT ID NCT01300143

Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers test whether adding high-dose radiotherapy to standard chemoembolization slows tumor growth better than chemoembolization alone in adults with hepatocellular carcinoma. Participants have liver tumors up to 9 cm that cannot be removed by surgery or treated with percutaneous therapy. One group receives chemoembolization alone, while the other receives one chemoembolization session followed by radiotherapy. The trial measures time until tumors progress on scans, along with side effects and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a combination of transarterial chemoembolization (TACE) with drug-eluting beads and high-dose conformational radiotherapy
What this could lead to
If it works, this could offer a stronger way to slow liver cancer in people who cannot have surgery or percutaneous treatment.
What could go wrong
This is a mid-stage trial, so the combination may not outperform chemoembolization alone or may cause more side effects. Results may not apply to all liver cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

126 people

The number who actually took part.

Started

Jun 2011

Finished

Oct 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years of age * ECOG 0-1 * life expectancy ≥ 6 months * Histologically proven hepatocellular carcinoma or proven according to radiological and biochemical criteria (EASL-AASLD) in cirrhotic patients * Maximum lesion size ≤ 9 cm * Non-eligible for surgery or percutaneous therapy * Premature Child-Pugh A or B (7 points for the Child-Pugh score) * AST and ALT \< 7 x UNL * Technical possibility of conformational external radiotherapy * Technical possibility of TACE * All the tumor mass must be able to be treated by TACE * Written consent signed by the patient * Patients affiliated to a social security system Exclusion Criteria: * Metastatic illness * Minimal lesion size ≤ 5 mm * Non controlled viral replication B * History of radiotherapy at abdominal level * Subjects capable of procreating without efficient contraception * pregnancy or nursing female patient * Contraindication of TACE or external conformational radiotherapy * Any other concomitant experimental treatment * Contraindication of Doxorubicin * Patients who are unable to respect enslaving respiratory constraints if used by sites * Patients who are unable to understand information and to follow protocol instructions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • AP-HP Henri Mondor

    Créteil, France

  • AP-HP Paul Brousse Villejuif

    Paris, France

  • CH Avignon

    Avignon, France

  • CHD les Oudairies

    La Roche-sur-Yon, France

  • CHR Orléans

    Orléans, France

  • CHR de Lille Hôpital Claude Huriez

    Lille, France

  • CHU Amiens

    Amiens, France

  • CHU Dijon

    Dijon, France

  • CHU Nantes

    Nantes, France

  • CHU d'Angers

    Angers, France

  • CHU de Bordeaux

    Bordeaux, France

  • CHU de Lyon

    Lyon, France

  • CHU de Nancy Hôpital Brabois

    Nancy, France

  • CHU de Reims

    Reims, France

  • Centre Eugene Marquis

    Rennes, France

  • Hôpital Tenon

    Paris, France

  • Institut Sainte Catherine

    Avignon, France

  • La Pitié-Salpétrière

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.